Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets cardio outcomes claim for Praluent in EU

Sanofi gets cardio outcomes claim for Praluent in EU

The two PCSK9 inhibitors are locked in a battle for the severe, high-risk end of the cholesterol market – mainly patients who are unable to control low-density lipoprotein (LDL) cholesterol ... Complicating the picture is a global intellectual property

Latest news

  • Dupixent bounce-back helps stem diabetes declines at Sanofi Dupixent bounce-back helps stem diabetes declines at Sanofi

    Another Regeneron-partnered drug – and another key component for Sanofi’s specialty medicines drive – is cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab), and while sales rose 55% year-on-year to 62m ... At the moment, Sanofi is losing

  • Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use? Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

    This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing

  • Segmentation, evolved Segmentation, evolved

    Along with results from its Odyssey Outcomes trial, Sanofi said that it plans to offer discounts of up to 69% to encourage payers to expand the use of the PCSK9 inhibitor. ... Research by Amgen, which has a PCSK9 called Repatha, suggests that two-thirds

  • Sanofi, Regeneron offer price cut for cholesterol drug Praluent Sanofi, Regeneron offer price cut for cholesterol drug Praluent

    The offer has been made just after the presentation of the large-scale ODYSSEY OUTCOMES at the American College of Cardiology (ACC) meeting in Orlando, which showed that adding PCSK9 inhibitor ... Both Praluent and Amgen’s rival PCSK9 inhibitor Repatha

More from news
Approximately 10 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Quick links

Infographics

Multimedia